Rybrevant approved for some non-small cell lung cancer patients
Incentives to boost vaccine uptake in Australia need multiple approaches
26 May 2021Many with inoperable pancreatic cancer are not prescribed cheap-but-essential medication
26 May 2021Rybrevant approved for some non-small cell lung cancer patients
Rybrevant (amivantamab-vmjw) was approved for adults with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, the U.S. Food and Drug Administration announced Friday.
